BioCentury | Nov 2, 2017
Company News

Monopar gets rights to Onxeo's Validive

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) granted Monopar Therapeutics Inc. (Northbrook, Ill.) exclusive, worldwide rights to Validive clonidine lauriad (BA-028). Onxeo will receive a $1 million license fee and is eligible for $108 million in milestones, including...
BioCentury | Oct 13, 2017
Clinical News

Onxeo's Livatag misses in Phase III for HCC

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) reported top-line data from the Phase III ReLive trial in 397 patients with unresectable hepatocellular carcinoma (HCC) showing that 20 and 30 mg/m2 doses of IV Livatag doxorubicin (BA-003) every 4...
BioCentury | Jul 8, 2017

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | May 12, 2017
Company News

Clinigen launches European managed access program for Beleodaq from Onxeo

Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for Beleodaq belinostat from Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Under the program, Beleodaq will be available...
BioCentury | Apr 7, 2017

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Mar 8, 2017
Company News

Management tracks

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said Chairman Leonard Bell will retire from its board, effective May 10. Fosun Kite Biotechnology Co. Ltd., a JV between Kite Pharma Inc. (NASDAQ:KITE) and Shanghai Fosun Pharmaceutical Group Co. Ltd....
BioCentury | Jan 27, 2017
Clinical News

Livatag: Completed Ph III ReLive enrollment

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Product: Livatag doxorubicin (Livatag doxorubicin Transdrug) (BA-003) Business: Cancer Molecular target: DNA Description: Nanoparticle formulation of doxorubicin Indication: Treat hepatocellular carcinoma (HCC) Endpoint: Overall survival (OS); time to progression,...
BioCentury | Dec 31, 2016

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Oct 3, 2016
Financial News

Onxeo completes private placement

Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Business: Cancer, Infectious, Other Date completed: 2016-09-30 Type: Private placement Raised: EUR12.5 million ($14 million) Shares: 5.4 million Price: EUR2.30 Shares after offering: 46.9 million Investors: Financiere de la...
BioCentury | Mar 7, 2016
Company News

DNA Therapeutics, Onxeo deal

Onxeo will acquire DNA Therapeutics for EUR1.7 million ($1.9 million) in stock up front. DNA Therapeutics, which develops signal-interfering DNA (siDNA) molecules for cancer indications, is also eligible to receive a milestone payment of EUR1...
Items per page:
1 - 10 of 27